Latest Blogs

Aug 10, 2017
In a divisive time, I look to my patients and see that there is more that unites us than divides us, and this is worth celebrating.
Aug 04, 2017
Never doubt that your voice and time matter when it comes to trying to change the world in a positive way. We as a community can come together and really make a difference, and you can see it firsthand any weekend in almost any city across the country.
Aug 03, 2017
The line of thinking that women can do without their breasts only makes breast cancer treatment easier for us as physicians, not for our patients. When it's your own body, every organ is vital.
Aug 03, 2017
The program is now available for this year's Research Community Forum Annual Meeting. Dr. Richard L. Schilsky invites you to join this unique event on September 24-25 in Alexandria, VA.
Subscribe to this column

L. Michael Glode, MD, FACP, FASCO

L. Michael Glodé, MD, FACP, FASCO, is a Professor Emeritus at the University of Colorado Cancer Center. He previously served as Chair of ASCO's Integrated Media and Technology and Cancer Education Committees. He is the author of prost8blog, a blog to help patients and their families understand various aspects of prostate cancer.

Dec 21, 2016
I cannot count the number of times I have thought to myself, “If it were not for the PSA, you would no doubt be out there playing golf, skiing, biking, taking a grandchild to the park, or just enjoying life.” Living from one PSA to the next is a bad way to mark the passing of time.
Aug 08, 2016
For prostate cancer, there are both challenges and some early positive results from immunotherapy trials that remain intriguing. One of the key challenges is identifying those patients who will benefit from the treatment.
Jun 05, 2016
Much of the news this week in prostate cancer will be generated by the ASCO Annual Meeting in Chicago. There are likely to be considerable news releases regarding precision medicine, and especially AR-V7, so I thought I would explain this a bit.
Feb 16, 2016
In what is the first (and hopefully one of many) example of using modern genomic methods to match treatments to the molecular defects in prostate cancer, the U.S. FDA has just granted “breakthrough designation” to olaparib.
Jan 06, 2016
One of the most frequent questions I hear in my clinic is, “Are we making any progress?” or, “Is there anything new out there?” The answer is always yes, or more properly, YES!
Nov 04, 2015
I think the facet of cancer most commonly misunderstood by non-scientists (patients/families) is heterogeneity. Several presentations at the Prostate Cancer Foundation Annual Retreat touched on this theme.

Pages